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ABSTRACT.
Purpose: To compare visual acuity (VA) change at 24 months in eyes with
clinically significant DME (CSDME) and good VA initially treated versus
initially observed in routine clinical practice.
Methods: Retrospective analysis of treatment-na€ıve eyes with CSDME and
good VA (baseline VA ≥ 79 letters), with at least 24 months of follow-up and
initially managed with treatment (intravitreal treatment and/or macular laser) or
observation with possible treatment after 4 months that were tracked in a
prospectively designed observational registry.
Results: We identified 150 eligible eyes (98 initially observed, 52 initially treated)
of 130 patients. The proportion of eyes with at least a 5-letter VA loss at 24 months
was not significantly different between the groups: 65% with initial observation and
42% with initial treatment (p = 0.39). However, initially observed eyes were more
likely to have a 10-letter VA loss at 24 months (OR = 4.6, p = 0.022). Most of
eyes in the initial observation group received at least one treatment (an intravitreal
injection in 66% and macular laser in 20%) during the 24-month period.
Conclusions: The risk of 5 letters loss was similar between both management
groups. However, initially observed eyes were more at risk of developing moderate
visual loss and more than 80% of them required treatment over 24 months.
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Introduction
Several treatments, such as macular
laser photocoagulation, surgery,
intravitreal injections of VEGF inhibi-
tors or steroids, have been proven to be
effective for diabetic macular oedema
(DME; Mitchell et al. 2011; Wells et al.
2016; Iglicki et al. 2018, 2019; Mello
Filho et al. 2019; Zur et al. 2019).
Recommendations from RCTs of
treatments for clinically significant dia-
betic macular oedema (CSDME) do
not apply to eyes with good vision as
the trials generally only included eyes
with impaired vision (Mitchell et al.
2011; Nguyen et al. 2012; Boyer et al.
2014; Heier et al. 2016; Wells et al.
2016). CSDME with good vision is,
however, commonly encountered in
clinical practice (Bressler et al. 2014).
Protocol V by DRCR.net was the
first RCT to compare visual outcomes
in centre-involving DME (CI-DME)
with good visual acuity (≥79 letters
read on a logarithm of the minimum
angle of resolution [logMAR] VA
chart, 20/25 Snellen equivalent) treated
with prompt macular laser photocoag-
ulation, prompt observation or prompt
intravitreal aflibercept. It reported no
significant difference in visual
1
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outcomes at two years among the three
groups, suggesting that initially
observed eyes may achieve similar out-
comes to those of initially treated eyes
with reduced risk of injection-related
adverse events and better cost-effec-
tiveness (Baker et al. 2019). However,
outcomes of patients in routine clinical
practice can differ from those in RCTs.
Information on how best to treat eyes
with DME and good vision is still
limited (Busch et al. 2019). This study
aimed to compare visual outcomes in
these eyes 24 months after they had
either received initial treatment versus
initial observation with treatment pos-




This was a retrospective analysis of data
from a prospectively designed outcomes
registry, the Fight Retinal Blindness!
Project (Gillies et al. 2014). Treatment-
na€ıve eyes with clinically significant
DME (CSDME; defined as DME meet-
ing one of these criteria: oedema within
500 lm of the centre of the fovea or at
least 1 disc area of swelling, any part of
which is within disc diameter of the
centre of fovea) with good VA (baseline
VA ≥ 79 letters read on a logMAR
chart or 20/25 Snellen equivalent) and
at least 24 months of follow-up were
identified. Participants in this analysis
included patients from practices in Aus-
tralia, France, Italy, New Zealand,
Switzerland and United Kingdom
(UK). Institutional approval was
obtained from the Royal Australian
and New Zealand College of Ophthal-
mologists Human Research Ethics
Committee, the French Institutional
Review Board (IRB; Societe Francaise
d’Ophtalmologie IRB), the IRCCS Ca
Granda Foundation Maggiore Policlin-
ico Hospital Milan, the Cantonal Ethics
Committee Zurich and the Caldicott
Guardian at the Royal Free London
NHS Foundation Trust. All patients
gave their informed consent. Informed
consent (“opt-in consent”) was sought
from patients in France, Italy, Switzer-
land and UK. Ethics committees in
Australia and New Zealand approved
the use of “opt-out” patient consent.
This study adhered to the tenets of the
Declaration of Helsinki and followed
the STROBE statements for reporting
observational studies (von Elm et al.
2008).
Data sources and measurements
The Fight Retinal Blindness! Registry
has a module that collects data from
eyes being managed for DME (Gillies
et al. 2014). Patients tracked in the
registry with treatment-na€ıve CSDME
and good VA could either be treated or
observed based on the clinician’s assess-
ment and in consultation with the
patient. One or both eyes were consid-
ered for the present analysis. Data were
obtained prospectively from each clini-
cal visit including the number of letters
read on a logMAR VA ETDRS (the
Early Treatment of Diabetic Retinopa-
thy) Chart (best of uncorrected, cor-
rected or pinhole), treatment given, the
central subfield thickness (CST [µm])
measured using spectral-domain optical
coherence tomography (OCT), the pres-
ence of CSDME and whether or not it
involved the centre of the fovea, proce-
dures and ocular adverse events. The
OCT scans were obtained using SD-
OCT devices: Heidelberg Spectralis
(Heidelberg, Germany); Optovue Avanti
(Fremont, California); Topcon 3D
OCT-2000 (Tokyo, Japan); and Cirrus
Zeiss (Oberkochen, Germany). CST was
calculated automatically using the same
instrument in each centre at all visits.
Demographic characteristics (age and
gender), duration and types of diabetes,
grading of diabetic retinopathy (DR)
and previous treatments received (catar-
act surgery and vitrectomy) were
recorded at baseline visit. Treatment
decisions, including the choice of treat-
ment, injection frequency and the num-
ber of macular laser treatments, were
collected over the follow-up period.
Patient selection and groups
All eligible eyes with treatment-na€ıve
CSDME and good vision at baseline
visit (as defined above) from 1 January
2010 to 31 March 2018 were considered
for the study, thereby allowing at least
24 months of observation after the
initial management decision. The 24-
month end-point was considered to be
the closest visit to 730 days of follow-
up 30 days. Eligible eyes that
received any intravitreal treatment,
such as vascular endothelial growth
factor (VEGF) inhibitors (ranibizumab
[0.5mg Lucentis, Genentech Inc/
Novartis], aflibercept [2mg Eylea,
Bayer] or bevacizumab [1.25mg Avas-
tin, Genentech Inc/Roche]) or steroid
implant (dexamethasone [700µg Ozur-
dex intravitreal implant, Allergan) and/
or macular laser photocoagulation at
the baseline visit were defined as “ini-
tially treated eyes”. Initially observed
eyes were defined as eligible eyes ini-
tially observed (i.e. no treatment
received) for at least 4 months. There
were no randomization for the manage-
ment allocation and no specific man-
agement protocols, so the decision to
treat or observe at baseline or during
the follow-up was determined by the
physician based on symptoms, VA and
OCT at the discretion of the physician
in consultation with the patient, thereby
reflecting routine clinical practice.
Outcomes
The main outcome was the proportion
of eyes with VA loss of at least 5 letters
from baseline at 24 months. Secondary
outcomes included the mean change in
VA and CST from baseline at
24 months, the proportion of eyes with
VA ≥ 84 letters (Snellen equivalent of
20/20), the proportion of eyes with VA
loss of ≥10 and ≥15 letters from base-
line at 24 months, time to receiving
first treatment (any treatment, macular
laser or intravitreal injection) in the
observation group, median number of
treatments, macular laser sessions and
visits over 24 months in each group.
Statistical analysis
Descriptive data were summarized
using the mean (standard deviation),
median (first and third quartiles) and
percentages where appropriate. Eyes
that completed at least 700 days of
follow-up were defined as “com-
pleters”. Demographic characteristics
were compared between initial man-
agement groups using t-tests, Wilcoxon
rank-sum tests, chi-square tests or
Fisher’s exact tests where appropriate.
The proportion of eyes with different
VA loss/gain and final VA of at least 84
letters at 24 months between groups
was compared using logistic mixed-
effects regression. Regression analysis
was adjusted for age, gender, VA/CST,
lens status, CI-DME and diabetic
retinopathy severity at baseline as fixed
effects, and nesting of outcomes within
practitioners and patients with bilateral
2
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disease as random effects. We also
compared VA and CST outcomes
between groups over 24 months using
mixed-effects longitudinal generalized
additive models with the interaction
between initial management and time
as the main predictor variable. Longi-
tudinal models included all visits of
included eyes and were adjusted for
age, VA/CST, lens status, diabetic
retinopathy severity and CI-DME at
baseline (fixed-effects), and practice
and intra-patient correlation for bilat-
eral cases (random-effects). We used
predictions from this model to plot
VA/CST and the difference in the mean
VA/CST change over 24 months in all
eyes. Negative binomial or zero-in-
flated Poisson regression models,
adjusted for age, VA/CST, lens status,
diabetic retinopathy and CI-DME at
baseline, practice and intra-patient cor-
relation with log days of follow-up
included as an offset variable was used
as appropriate to compare the number
of injections and visits between groups.
Cox proportional hazards models
adjusted for age, VA/CST, lens status,
diabetic retinopathy severity and CI-
DME at baseline, practice and intra-
patient correlation were used to com-
pare the time to the first treatment (any
treatment, macular laser or intravitreal
injection) over 24 months in the initial
observation management group.
Kaplan–Meier survival analysis was
used to plot survival curves to first
treatment, injection and laser over
24 months in the initial observation
management group. A p-Value of 0.05
or less was considered statistically sig-
nificant. All analyses were conducted
using R software version 3.6.3 (http://
www.R-project.org/) with the
glmmTMB package (V0.2.3) for linear
mixed-effects and logistic mixed-effects
regression, the emmeans package
(V1.3.3) for pairwise comparison of
adjusted means, the mgcv package
(V1.8–24) for the generalized additive
(mixed) model computation, and the
coxme package (V2.2–10) and the sur-




A total of 150 treatment-na€ıve
CSDME eyes (98 initial observation
and 52 initial treatment) of 130 patients
from 1 January 2010 to 31 March 2018
Fig. 1. Flowchart showing the number of eyes remaining at each selection criterion.
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were identified. The flowchart showing
the number of eyes at each selection
criterion is shown in Fig. 1. Table 1
summarizes the baseline characteristics
of the eyes in each of the groups.
Overall, the mean (SD) age was 60 (11)
and 32% were women. Eyes initially
managed with observation had better
baseline VA (mean 84 versus 82 letters;
p < 0.01), thinner CST (mean 308 ver-
sus 338 µm; p = 0.012) and less likely
to have CSDME which involved the
foveal centre (63% versus 89%;
p < 0.01) than initially treated eyes.
The initial observation group was sig-
nificantly older (62 versus 57 years in
the treatment group; p = 0.010) and
had less type 1 diabetes (4% versus
20% in the treatment group; p < 0.01).
Visual outcomes at 24 months
The percentage of eyes with at least a 5-
letter VA loss at 24 months (primary
outcome) between initial observation
and initial treatment was 65% versus
42% (Odds Ratio [OR] = 1.6 [0.5, 5.1],
p < 0.39; Table 2). Eyes in the initial
observation group were more likely to
have a 10-letter and 15-letter VA loss at
24 months (OR = 4.6 [1.3, 17.0],
p = 0.022 and OR = 18.5 [0.8,410.0],
p = 0.065, respectively). Figure 2A
describes the crude mean (SD) VA at
12 and 24 months. The proportion of
eyes with VA ≥ 84 letters (Snellen
equivalent of 20/20) at 24 months was
29% with initial observation and 35%
with initial treatment (OR = 0.8 [0.3,
2.6], p = 0.77). Eyes that were initially
treated seemed more likely to have
driving level vision (VA ≥ 69 letters
logMAR or 20/40 Snellen equivalent)
after 24 months of treatment (92%
versus 72% for initially observed eyes,
p = 0.09; Table 2). The adjusted mean
VA over 24 months, using longitudinal
generalized additive models, is shown
in Fig. 3A. The adjusted mean (95%
CI) difference in the VA change was
significantly in favour of initial treat-
ment for most of the 24 months (8
[10, 5] for observation versus 3
[6, 0] letters for treatment, p = 0.020;
Fig. 3B and Table 2).
Macular thickness at 24 months
Figure 2B reports the crude mean (SD)
CST change at 12 and 24 months. The
adjusted mean CST change over
24 months using adjusted longitudinal
generalized additive models is shown in
Fig. 3C. The adjusted mean (95% CI)
difference in the CST change was sig-
nificantly in favour of initial treatment
from 2 to 20 months of follow-up but
was similar by the end of the 24-month
follow-up (16 [34, 2] for observation
versus 24 [43, 6] µm for treatment,
p < 0.01; Fig. 3D and Table 2).
Treatments and visits over 24 months
At least one intravitreal injection was
given to 66% of eyes in the initial
observation group over 24 months,
20% received macular laser and 13%
received both (Fig. 4). Eyes in the
observation group that received at least
one intravitreal injection had a mean
(SD) change in VA of 12 (11) letters
from baseline to the time of the injec-
tion at a median (Q1, Q3) time of 554
(322, 827) days (Table 2). Eyes with
thicker maculae at baseline were more
likely to receive an intravitreal injection
over 2 years (hazard ratio [HR] = 2.3
[1.1, 4.9] for every 100 lm increase of
CST, p = 0.027).
The median (Q1, Q3) number of
intravitreal injections and macular laser
sessions over 24 months was similar
between groups (6 (3, 10) versus 6 (3,
10) injections, p = 0.97 and 0 (0, 0)
versus 0 (0, 1) laser sessions, p = 0.20 in
the initial observation and initial treat-
ment groups, respectively). The vast
majority (97%) of intravitreal treatment
in both groups were with VEGF inhi-
bitors while the dexamethasone implant
accounted for the remaining 3%. How-
ever, initially observed eyes had a
significantly higher median number of
visits over 24 months (17 (12, 21) versus
13 (9, 18) visits for initially treated eyes,
p < 0.01; Table 2).
Discussion
We used the FRB! international obser-
vational outcomes database to explore
the effect of initial management on
visual outcomes in treatment-na€ıve eyes
with CSDME (including centre-involv-
ing and non-centre-involving DME)
and good vision (baseline VA ≥ 79
letters or 20/25 Snellen equivalent) in






Eyes, n 150 98 52
Patients, n 130 83 50
Female, n (%) 42 (32) 31 (37) 13 (26) 0.16
Age years, mean (SD) 60 (11) 62 (9) 57 (13) 0.010
Type 1 Diabetes, n (%) 13 (10) 3 (4) 10 (20) <0.01
Diabetes duration years, mean (SD) 14 (10) 14 (9) 15 (11) 0.72
Lens status (phakic), n (%) 136 (91) 90 (92) 46 (89) 0.70
Diabetic Retinopathy grades, %
Mild NPDR 17 17 17 0.21
Moderate NPDR 43 39 50
Severe NPDR 33 39 23
PDR – Low Risk 5 4 6
PDR – High Risk 2 1 4
Visual acuity logMAR letters, mean (SD) 83 (3) 84 (3) 82 (3) <0.01
Central subfield thickness lm, mean (SD) 320 (67) 308 (62) 338 (70) 0.012
Type of DME, %
Centre-involving CSDME 72 63 89 <0.01
Non-centre-involving CSDME 28 37 11
Initial management, n (%)
Observation 98 (65) 98 (100) – –
Bevacizumab 8 (5) – 8 (15)
Ranibizumab 22 (14) – 22 (42)
Aflibercept 9 (6) – 9 (18)
Dexamethasone implant 1 (1) – 1 (2)
Macular laser photocoagulation 12 (9) – 12 (23)
CSDME = Clinically Significant Diabetic Macular Oedema; CST = Central Subfield Thickness;
DME = Diabetic Macular Oedema; n = Number; NPDR = Non-Proliferative Diabetic
Retinopathy; PDR = Proliferative Diabetic Retinopathy; SD = Standard Deviation; VA = Visual
Acuity (logMAR letters).
Significant p-values are highlighted in bold.
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routine clinical practice. The proportion
of eyes developing 5-letter VA loss at
24 months was not significantly differ-
ent between eyes initially treated and
eyes initially observed for at least
4 months. This finding is consistent
with the DRCRnet protocol V that
found no significant difference in the
rates of 5 letter VA loss over 2 years
between the following 3 groups: initial
observation plus aflibercept only if VA
decreased, initial focal/grid laser plus
aflibercept only if VA decreased or
prompt aflibercept (Baker et al. 2019).
The secondary outcomes in our
study may be of more clinical interest.
We found that eyes initially observed
had significantly greater loss of
adjusted mean change in VA, including
significantly higher risk of 10-letter VA
loss over 24 months. This differs from
the results of DRCR.net Protocol V,
which did not find any significant
difference regarding the mean change
in VA and the proportion of 10-letter
vision loss at 2 years. The study design,
different inclusion/exclusion criteria and
a less rigorous protocol of treatment
and follow-up in a routine clinical
practice setting may be reasons for the
poorer visual outcomes that we found in
the initial observation group (Hole-
kamp et al. 2018). Visual outcomes in









Odds ratio, mean difference
or ratio (95% CI) p-Value
Primary outcomes
≥5-letter VA loss, n (%) 64 (65) 22 (42) 1.6 (0.5, 5.1) † 0.39
Secondary outcomes
Baseline VA letters, mean (SD) 84 (3) 82 (3)
Baseline VA Snellen equivalent, mean 20/25 20/25
VA change from baseline to 24 months letters,
crude mean (95% CI)
10 (13, 8) 3 (6, 0) <0.01
VA change from baseline to 24 months letters,
adjusted mean (95% CI)
8 (10, 5) 3 (6, 0) 4 (8, 1)‡ 0.020
≥10-letter loss from baseline, n (%) 39 (40) 10 (19) 4.6 (1.3, 17.0)† 0.022
≥15-letter loss from baseline, n (%) 29 (30) 2 (4) 18.5 (0.8, 410.0)† 0.065
VA at 24 months letters, mean (SD) 74 (13) 79 (9)
VA at 24 months Snellen equivalent, mean 20/32 20/25
≥84 letters (20/20 or better), n (%) 28 (29) 18 (35) 0.8 (0.3, 2.6)† 0.77
≥69 letters (20/40 or better), n (%) 73 (75) 48 (92) 0.3 (0.1, 1.2)† 0.09
Baseline CST lm, mean (SD) 307.9 (61.8) 338.4 (69.8)
CST change from baseline to 24 months lm,
crude mean (95% CI)
0 (19, 19) 32 (56, 9) 0.033
CST change from baseline to 24 months lm,
adjusted mean (95% CI)
16 (34, 2) 24 (43, 6) +8 (14, 30)‡ <0.01
Injections, median (Q1, Q3) 6 (3, 10) 6 (3, 10) 1.1 (0.8, 1.4)§ 0.77
Proportion of eyes receiving any treatment in
the observation group
77 (79) NA
Proportion of eyes receiving at least one injection
in the observation group, n (%)
65 (66) NA
Time until first injection days, median (Q1, Q3) 554 (322, 827) –
VA at first injection letters, mean (SD) 72 (11) –
VA change at first injection letters, mean (SD) 12 (11) –
<5-letters loss, n (%) 21 (21) –
≥5 and <10-letters loss, n (%) 13 (13) –
≥10 letters loss, n (%) 31 (32) –
Proportion of eyes receiving at least one laser
photocoagulation in the observation group, n (%)
20 (20) NA
Time until first laser days, median (Q1, Q3) 320 (225, 607) –
VA at first laser letters, mean (SD) 8 (9) –
Laser photocoagulation sessions, median (Q1, Q3) 0 (0, 0) 0 (0, 1) 0.8 (0.4, 1.5)§ 0.48
Visits, median (Q1, Q3) 17 (12, 21) 13 (9, 18) 1.6 (1.3, 2.0)§ <0.01
CI = Confidence Interval; CST = Central subfield thickness; n = Number; Q1 = First Quantile; Q3 = Third Quantile; SD = Standard Deviation; VA =
Visual Acuity.
Significant p-values are highlighted in bold.
† Calculated from logistic mixed-effects regression models adjusting for age, VA/CST, lens status, centre-involving diabetic macular oedema, grade of
diabetic retinopathy at baseline (fixed effects), and practice and intra-patient correlation for bilateral cases (random effects).
‡ Calculated from non-linear mixed-effects regression models adjusting for age, VA/CST, lens status, centre-involving diabetic macular oedema, grade
of diabetic retinopathy at baseline (fixed effects), and practice and intra-patient correlation for bilateral cases (random effects).
§ Adjusted ratio (95% CI) of number of injections, laser photocoagulations or visits between observation versus treatment group. It was calculated
from Poisson regression models adjusting for age, VA/CST, lens status, centre-involving diabetic macular oedema, grade of diabetic retinopathy at
baseline (fixed effects), and practice and intra-patient correlation for bilateral cases (random effects).
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observational studies have generally
been inferior to those reported by RCTs
(Patrao et al. 2016; Egan et al. 2017;
Bhandari et al. 2019; Lukic et al. 2019).
At least one intravitreal injection was
given to 66% of eyes in the initial
observation group over 24 months,
20% received laser photocoagulation
and 13% received both. This is higher
than reported by the Protocol V study,
with only 40% of the observation and
30% of the laser photocoagulation
groups requiring at least one injection
of aflibercept over 2 years (Baker et al.
2019). We included only eyes with DME
that were treatment-na€ıve, whereas pro-
tocol V also included pretreated eyes
(approximately 15% of the observation
and laser photocoagulation cohorts;
Baker et al. 2019). Those eyes may have
benefited from the effect of previous
laser or intravitreal treatment and might
be less likely to require further treatment.
A recent secondary analysis of Protocol
V showed that initially observed DME
eyes with contralateral eye concomi-
tantly treated with intravitreal VEGF
inhibitors for DME are at increased risk
of receiving an early injection (Glassman
et al. 2020). Three patients were in that
case in our study, so it is unlikely that
those patients substantially increased the
likelihood of receiving an injection.
The mean (SD) loss of VA until the
first injection in the observation group
was 12 (12) letters. Intravitreal treatment
was started with relatively high VA loss
in our routine clinical practice observa-
tional study but similar to the Protocol
V study treatment initiation criteria (i.e.,
at least 10 letters VA loss from baseline
at one visit). A retrospective study
comparing one year outcomes of treated
and untreated DME eyes with good VA
reported that continuing observation if
VA decreases ≥5 letters within 6 months
led to worse visual outcome at one year
compared with initiating treatment
(Busch et al. 2019). The introduction of
treatment was based on symptoms, VA
and OCT at the discretion of the physi-
cian in consultation with the patient
agreement, thereby representing routine
clinical practice. Several studies have
suggested that compliance and adher-
ence to treatment may be difficult in
patients with DME in routine clinical
practice due to a range of factors
including visit and treatment burden,
not just of the eye disease but of
diabetes in general and its comorbidities
(Schnabel et al. 2016), which may result
in worse long-term visual outcomes
(Ehlken et al. 2018; Weiss et al. 2018).
It is worth noting that the initial
treatment group did not experience a
clinically significant visual gain and did
not have a significantly higher propor-
tion of eyes with VA ≥ 84 letters over
24 months than the initial observation
group. This is probably due to a ceiling
effect that is usually observed in eyes
with DME and good vision (Mitchell
et al. 2011; Nguyen et al. 2012; Koro-
belnik et al. 2014; Heier et al. 2016;
Wells et al. 2016; Busch et al. 2019).
However, more initially treated eyes
had driving vision after 24 months of
treatment. Early treatment may there-
fore reduce the risk of loss of indepen-
dence, which may have a dramatic
impact on the quality of life.
The median number of injections in
both groups over 24 months was
Fig. 2. (A) Visual acuity and (B) change in central subfield thickness at 24 months. For each box-and-whisker plot with jitter, the horizontal bar
within the box represents median; top and bottom of box, interquartile range; Upper and lower whisker extends to the closest observed data point
below the upper or above the lower quartile plus 1.5 times the interquartile range. Jitters and Outlying values are plotted as black spots and circles,
respectively. Values in panel A at or above the horizontal dashed line (84 letters) represent visual acuity of 20/20 or better.
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remarkably similar even though treat-
ment was delayed for at least 4 months
in the observation group. A similar
observation was made by the
DRCR.net protocol V study group
(Baker et al. 2019). Eyes in the initial
observation group had significantly
more visits over 24 months. These
findings suggest that a delay in the
initiation of treatment results in a
requirement of more intensive treat-
ment and monitoring to maintain good
vision. The inconvenience of starting
treatment early may thus be offset by
reducing the long-term visit burden for
both patients and physicians. The pro-
posed benefits of deferring treatment,
such as reduced risk of endophthalmitis
and the economic benefit for the health
care system in savings on drug and
procedures, deserve to be reconsidered
(Baker et al. 2019). Further studies are
warranted to address these concerns.
We reported that initially treated
eyes led to better anatomical outcomes
compared to observation with a greater
improvement of CST during most of
24 months. We also found that initially
observed eyes with thicker CST at
baseline had an increased risk of hav-
ing at least one intravitreal injection
over 24 months as recently described in
a secondary analysis from DRCR pro-
tocol V (Glassman et al. 2020).
This study has several strengths.
Observational studies provide data on
the ability of an intervention to
achieve its intended purpose in clini-
cal practice. Our data are representa-
tive of a wide variety of international
practices and practitioners. Though
there is variability in the quality of
data in observational studies, the
FRB! system includes quality assur-
ance measures that preclude out of
range and missing data (Gillies et al.
2014). Well-designed observational
studies are unlikely to overestimate
the effect of treatment compared with
the results of randomized clinical tri-
als (Concato et al. 2000).
Fig. 3. Line graphs showing (A) the mean predicted visual acuity in logMAR letters; (B) the difference in the mean change in VA between initial
observation (pink) and initial treatment (green); (C) the mean predicted central subfield thickness (CST, solid lines) and (D) the difference in mean
change in CST between initial observed and treated eyes over 24 months. The grey-shaded area in figures B and D represents the 95% confidence
interval. Red-dashed lines in B and D indicate areas where the 95% confidence interval does not intersect with 0.
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We acknowledge several limitations
that are mostly inherent in observa-
tional studies. First, treatment deci-
sions in routine clinical practice are
made without reference from a guided
management protocol or reading centre
and are likely to differ among physi-
cians and centres, particularly in dif-
ferent countries. We included nesting
of outcomes within practitioners in our
models to help account for these
effects. Second, a lack of prospective
randomization resulted in significant
differences in baseline characteristics
between the initial observation and
initial treatment groups. However, we
have attempted to control for these
imbalances by adjusting the statistical
analysis for potential unbalanced con-
founders such as age, gender, lens
status, VA/CST, CI-DME and the
severity of DR at baseline although
we did not have data on glycaemic and
blood pressure control which may have
influenced our results. Third, our study
may have been underpowered due to
the relatively small sample sizes,
though we were able to detect statisti-
cally and clinically significant differ-
ences in a number of secondary
outcomes. A priori power analysis
calculation for detecting a 25% differ-
ence in the proportion of 5-letter VA
loss over 24 months with 80% power
(a error = 0.05) via logistic regression
suggested a sample size of 149 (ratio of
2:1 between groups) would be suffi-
cient. Fourth, we included all types of
CSDME in our studies, whereas Pro-
tocol V included only CI-DME. We
adjusted outcomes to control for base-
line foveal involvement. A sensitivity
analysis on the cohort of eyes with CI-
DME did not affect the main findings
of the primary analysis (Tables S1 and
S2, Figs S1–S3). Overall mean CST was
similar to Protocol V study (320 versus
311 µm in Protocol V; Baker et al.
2019). Fifth, we were unable to com-
pare the risk of diabetic retinopathy
progression between both strategies
(Gross et al. 2015; Iglicki et al. 2018)
and to address the influence of possible
functional predictive imaging factors
on the results (Busch et al. 2020; Zur
et al. 2020).
In conclusion, CSDME eyes with
good vision initially managed with
treatment versus observation with pos-
sible treatment after 4 months had
similar rates of 5-letter visual loss over
24 months. However, initially observed
eyes were more at risk of developing
moderate visual loss and more than
80% of them subsequently required
treatment with more follow-up visits
over 24 months. Initiating treatment
may be a better management option for
good vision DME in the case of
patients with weak adherence and
compliance since it decreases the risk
of visual loss and reduces the patient’s
management burden from diabetes and
associated comorbidities. The develop-
ment of less invasive or more durable
treatments may further tilt the balance
in favour of initiating treatment earlier.
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may be found in the online version of
this article:
Fig. S1. (A) Visual acuity and (B)
change in central subfield thickness at
24 months when only eyes with center-
involving diabetic macular edema are
included.
Fig. S2. Line graphs showing (A) the
mean predicted visual acuity in log-
MAR letters; (B) the difference in the
mean change in VA between initial
observation (pink) and initial treat-
ment (green); (C) the mean predicted
central subfield thickness (CST, solid
lines) and (D) the difference in mean
change in CST between initial observed
and treated eyes over 24 months when
only eyes with center-involving diabetic
macular edema are included.
Fig. S3. Kaplan–Meier plots for time
to first treatment, intravitreal injection
and laser photocoagulation in the ini-
tial observation group when only eyes
with center-involving diabetic macular
edema are included.
Table S1. Baseline characteristics of the
study groups when only eyes with
center-involving diabetic macular
edema are included.
Table S2. 24-month outcomes when
only eyes with center-involving diabetic
macular edema are included.
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